Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer
Study Information
Alliance Study ID: NCCTG-N0041
NCT Study ID (ClinicalTrials.gov): NCT00006010
Disease or Cancer Type: Gastrointestinal Cancers – Pancreatic / Gastric / Esophageal / Liver / Biliary
Alliance Study Chair: Steven R. Alberts, MD
Status: COMPLETED
Study Description
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of gemcitabine plus docetaxel in treating patients who have unresectable or metastatic liver cancer.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information